Weekly platinum chemotherapy for recurrent ovarian cancer

British Journal of Cancer

Volumn 86, Issue 1, 2002, Pages 2-4

  Clamp, A ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; MITOXANTRONE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; EDITORIAL; FEMALE; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; META ANALYSIS; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 0037033709     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600062     Document Type: Editorial

References (31)

1. An updated analysis of a randomised study of single agent paclitaxel given weekly versus every three weeks to patients with ovarian cancer treated with prior platinum therapy
2. Treatment of relapsed carcinoma of the ovary with single agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy
3. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
4. Weekly paclitaxel/carboplatin as first-line chemotherapy in late relapses of epithelial ovarian cancer. Preliminary results
5. Weekly cisplatin given for two months versus cisplatin plus cyclophophamide given for five months aker cytoreductive surgery for advanced ovarian cancer
6. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen
7. Docetaxel administered on a weekly basis for metastatic breast cancer
8. Mature results of a prospective randomised trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma
9. Cisplatin dose intensity in advanced ovarian cancer: A randomised study of conventional dose versus dose-intense cisplatin monochemotherapy
10. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory, to or relapsing within 12 months after platinum-containing chemotherapy
11. Predictors of response to subsequent chemotherapy in platinum-pretreated ovarian cancer. A multi-variate analysis of 704 patients
12. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
13. Mitoxantrone plus paclitaxeh A highly active salvage regimen for heavily pretreated ovarian cancer
14. Phase II trial of weekly single agent paclitaxel in platinum and paclitaxel refractory ovarian cancer
15. A phase II trial of weekly paclitaxel/carboplatin as salvage chemotherapy in patients with relapsed ovarian cancer
16. Phase II study of prolonged oral etoposide in refractory ovarian cancer
17. Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomised study
18. Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity, analysis
19. Phase II trial of chronic low dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer
20. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
21. Low-dose oral etoposide in epithelial cancer of the ovary
22. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
23. A large phase II trial of paclitaxel administered as a weekly one hour infusion to patients with metastatic breast cancer
24. Weekly cis-diammine dichloroplatinum (II): Active third line chemotherapy in ovarian carcinoma- a preliminary report
25. Topoisomerase II inhibitor-related acute myeloid leukaemia
26. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A gynecologic oncology group study
27. Weekly cisplatinum as third line chemotherapy in advanced ovarian carcinoma. A phase II study
28. Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum-resistant disease
29. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer